CA
MRTX

Crewe Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Crewe Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-33
Closed -$1.23K – 1028
2023
Q1 		$1.23K Hold
33
– – ﹤0.01% 743
2022
Q4 		$1.5K Sell
33
-34
-51% -$2.2K ﹤0.01% 878
2022
Q3 		$5K Buy
67
+20
+43% +$1.48K ﹤0.01% 867
2022
Q2 		$3K Buy
+47
New +$2.99K ﹤0.01% 943

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Crewe Advisors's MRTX Position: Q2 2023 in Review

Crewe Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2023, closing a stake of 33 shares — an estimated $1.23K sold.

Crewe Advisors first reported a position in MRTX in Q2 2022 and held it in 4 quarters. The position peaked at $5K in Q3 2022. 207 funds tracked by Wall St. Rank hold MRTX as of Q2 2023.

  • Crewe Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Crewe Advisors sold 33 Mirati Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $1.23K.
  • Crewe Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2022 and held it in 4 quarters.
  • Crewe Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $5K in Q3 2022.
  • 207 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Crewe Advisors's 13F filing for Q2 2023, filed 28 Jul 2023.